RxDoctor Payments Data

Michael Disiena, MD

Gastroenterology · Torrington, CTNPI 1932593837

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $30,030 of the $39,476 with a category attached, or 76.1%. Phathom Pharmaceuticals, Inc. accounts for 67.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $26,400 and has fallen 74.1% since, to $6,846 in 2025. Among gastroenterology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,476in general payments, 2019–2025

Across 103 payments — averaging $383.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$27K
  • Aimmune Therapeutics, Inc.$6K
  • Regeneron Healthcare Solutions, Inc.$5K
  • AbbVie$506
  • UCB, Inc.$379
  • Sanofi$294
  • plus $674 from 12 others

What the payments were for

  • Speaking & faculty fees$30,03076%
  • Travel & lodging$6,15916%
  • Food & beverage$3,2878%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,476 in reported general payments places this provider in the 90th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$163,252
Medicare patients
270
Services billed
7,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VoqueznaVonoprazan Fumarate14$14,743
SutabSod Sulf/Pot Chloride/Mag Sulf34$5,526
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates57$3,452
Mesalamine26$3,190
Pantoprazole Sodium189$2,692
Omeprazole64$1,255
Budesonide EcBudesonide12$1,131
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg36$671
Esomeprazole Magnesium13$602
Lansoprazole22$524
Sucralfate15$295
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl27$290
Dicyclomine Hcl15$190
Famotidine13$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Phathom Pharmaceuticals, Inc.Voquezna$26,785$14,74314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Torrington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →